SCHEMBL15034098

SCHEMBL15034098

CC1(C)CN(C(=O)c2cccc(COc3ccccc3)c2)CCN1C(=O)c1ncn(-c2cccc(Cl)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 2/20 0.44
SMN1; SMN2 Q16637 6/20 0.43
NPC1 O15118 6/20 0.43
RAB9A P51151 6/20 0.43
ALDH1A1 P00352 5/20 0.43
GAA P10253 2/20 0.43
TP53 P04637 3/20 0.42
LMNA P02545 3/20 0.42
HTT P42858 2/20 0.42
RECQL P46063 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 3/20 0.41
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NR4A2 P43354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020006 0.88 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1TP53HTTMEN1
SCHEMBL15019972 0.88 SLC6A7 (0.43) MGLLSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL15034067 0.87 GRM5 (0.47) MGLLALDH1A1GRM5
SCHEMBL15034043 0.86 MAPT (0.41) MGLLALDH1A1KMT2AMAPTGRM5
SCHEMBL15034093 0.85 WNK1 (0.47) MGLLALDH1A1GRM5
SCHEMBL15034052 0.84 TSHR (0.43) MGLLSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL15034096 0.84 GRM5 (0.38) MGLLALDH1A1MAPTGRM5
SCHEMBL15034061 0.84 MGLL (0.45) MGLLSMN1; SMN2HTTMAPTGRM5
SCHEMBL15034215 0.83 HPGD (0.43) MGLLSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL15034036 0.83 ALDH1A1 (0.44) MGLLSMN1; SMN2ALDH1A1TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 MGLL 2123/4885SMN1; SMN2 2592/4885NPC1 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.